DOPS ( DrugBank: DOPS )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	3
17	多系統萎縮症	2

6. パーキンソン病

---

臨床試験数 : 2,298 /  薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03567447 (ClinicalTrials.gov)	August 17, 2018	21/5/2018	Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)	Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)	Parkinson Disease;Falls Patient	Drug: Droxidopa;Other: Placebo	St. Joseph's Hospital and Medical Center, Phoenix	H. Lundbeck A/S;Arizona State University	Recruiting	30 Years	83 Years	All	10	Phase 2	United States
2	NCT02812147 (ClinicalTrials.gov)	May 2016	25/5/2016	Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease	Effect of L-Dihydoxyphenylserine (L-DOPS, Northera) a Central and Peripheral Norepinephrine Agent on Locomotion, Postural Stability (Balance), and Fall Risk Reduction in Parkinson Disease (PD)	Parkinson Disease	Drug: L-DOPS;Drug: Placebo	St. Joseph's Hospital and Medical Center, Phoenix	Arizona State University, Tempe	Active, not recruiting	30 Years	83 Years	All	20	Phase 2	United States
3	NCT00547911 (ClinicalTrials.gov)	October 2007	19/10/2007	Augmenting Effects of L-DOPS With Carbidopa and Entacapone	L-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and Entacapone	Parkinson Disease;Multiple System Atrophy;Autonomic Nervous System Diseases	Drug: Droxidopa;Drug: Carbidopa;Drug: Entacapone	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Terminated	18 Years	N/A	All	14	Phase 1/Phase 2	United States

17. 多系統萎縮症

---

臨床試験数 : 118 /  薬物数 : 163 - (DrugBank : 49) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 112

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02071459 (ClinicalTrials.gov)	January 21, 2014	21/2/2014	Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA	Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo	Multiple System Atrophy	Drug: L-Threo DOPS;Drug: placebo	University Hospital, Toulouse	NULL	Completed	30 Years	80 Years	All	107	Phase 2/Phase 3	France
2	NCT00547911 (ClinicalTrials.gov)	October 2007	19/10/2007	Augmenting Effects of L-DOPS With Carbidopa and Entacapone	L-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and Entacapone	Parkinson Disease;Multiple System Atrophy;Autonomic Nervous System Diseases	Drug: Droxidopa;Drug: Carbidopa;Drug: Entacapone	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Terminated	18 Years	N/A	All	14	Phase 1/Phase 2	United States

先頭へ